{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:35:54Z","timestamp":1760729754201},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.neuropharm.2006.03.009","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T17:08:55Z","timestamp":1147194535000},"page":"141-145","source":"Crossref","is-referenced-by-count":33,"title":["Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety"],"prefix":"10.1016","volume":"51","author":[{"given":"Sandy","family":"Hogg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line","family":"Michan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Jessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2006.03.009_bib1","first-page":"1","article-title":"Practice guidelines for the treatment of patients with panic disorder","volume":"155","author":"APA","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2006.03.009_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1017\/S1092852900028595","article-title":"Efficacy Comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials","volume":"7","author":"Gorman","year":"2002","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01244820","article-title":"The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer","volume":"88","author":"Hyttel","year":"1992","journal-title":"J. Neural. Transm. Gen. Sect."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib4","series-title":"New Concepts in Anxiety","first-page":"288","article-title":"Neurotransmitters in the dorsal periaqueductal gray and the animal models of panic anxiety","author":"Graeff","year":"1991"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0166-4328(93)90097-A","article-title":"Role of the amygdala and periaqueductal gray in anxiety and panic","volume":"58","author":"Graeff","year":"1993","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF00439553","article-title":"Effects of serotonin receptor antagonists on PAG stimulation induced aversion: different contributions of 5HT1, 5HT2 and 5HT3 receptors","volume":"97","author":"Jenck","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/BF02244609","article-title":"5-HT1C receptors in the serotonergic control of periaqueductal gray induced aversion in rats","volume":"100","author":"Jenck","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0014-2999(90)90271-7","article-title":"The effect of antidepressants on aversive periaqueductal gray stimulation in rats","volume":"177","author":"Jenck","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0165-1781(95)02673-K","article-title":"Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: Elements of face and predictive validity","volume":"57","author":"Jenck","year":"1995","journal-title":"Psychol. Res."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0924-977X(97)00055-2","article-title":"Antiaversive effects of 5HT2c receptor agonists and fluoxetine in a model of panic-like anxiety in rats","volume":"8","author":"Jenck","year":"1998","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2006.03.009_bib11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/026988119901300209","article-title":"The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats","volume":"13","author":"Jenck","year":"1999","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0924-977X(01)00100-6","article-title":"Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors","volume":"11","author":"Kasper","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2006.03.009_bib31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0006-3223(93)90010-B","article-title":"Valproate treatment of panic disorder and lactate-induced panic attacks","volume":"33","author":"Keck","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archpsyc.1988.01800290053007","article-title":"Secondary depression in panic disorder and agoraphobia. I. Frequency, severity, and response to treatment","volume":"45","author":"Lesser","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib14","unstructured":"Mitchell, P.J., Hogg, S. Escitalopram exhibits potent antidepressant-like activity in the resident-intruder paradigm. Int. J. Neuropsychopharmacol., submitted for publication."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00004714-199208000-00007","article-title":"Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial","volume":"12","author":"Modigh","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1034\/j.1600-0773.2001.d01-118.x","article-title":"Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model","volume":"88","author":"Montgomery","year":"2001","journal-title":"Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.neuropharm.2006.03.009_bib17","first-page":"103","article-title":"Escitalopram and paroxetine in fixed doses for the treatment of social anxiety disorder (SAD)","volume":"57","author":"Montgomery","year":"2003","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0028-3908(03)00138-2","article-title":"The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracelluler 5-HT in the frontal cortex of freely moving rats","volume":"45","author":"M\u00f8rk","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3171\/jns.1969.30.1.0014","article-title":"Sensations evoked by stimulation of the midbrain of man","volume":"30","author":"Nashold","year":"1969","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib21","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib22","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1177\/02698811000142S104","article-title":"Panic: course, complications and treatment of panic disorder","volume":"14","author":"Pollack","year":"2000","journal-title":"J Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2006.03.009_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.jcp.0000195383.96383.25","article-title":"New possibilities in the treatment for panic attacks in elderly patients: escitalopram versus citalopram","volume":"26","author":"Rampello","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","article-title":"Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities","volume":"167","author":"S\u00e1nchez","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF00428199","article-title":"Anti-aversive role of serotonin in the dorsal periaqueductal gray matter","volume":"85","author":"Schutz","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib27","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized. double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2006.03.009_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1017\/S0033291700046419","article-title":"Phenelzine in phobic anxiety: a controlled trial","volume":"3","author":"Tyrer","year":"1973","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2006.03.009_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0447.2000.tb10947.x","article-title":"Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors","volume":"403","author":"Zohar","year":"2000","journal-title":"Acta. Psychiatr. Scand. Suppl."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839080600058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839080600058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T17:00:18Z","timestamp":1547658018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839080600058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S002839080600058X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2006.03.009","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}